Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
OPXA's Cash to Debt is ranked higher than
93% of the 901 Companies
in the Global Biotechnology industry.

( Industry Median: 30.71 vs. OPXA: No Debt )
Ranked among companies with meaningful Cash to Debt only.
OPXA' s Cash to Debt Range Over the Past 10 Years
Min: 0  Med: 11.73 Max: No Debt
Current: No Debt
Equity to Asset 0.67
OPXA's Equity to Asset is ranked lower than
51% of the 675 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. OPXA: 0.67 )
Ranked among companies with meaningful Equity to Asset only.
OPXA' s Equity to Asset Range Over the Past 10 Years
Min: -1246  Med: 0.16 Max: 0.78
Current: 0.67
-1246
0.78
Interest Coverage No Debt
OPXA's Interest Coverage is ranked higher than
89% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. OPXA: No Debt )
Ranked among companies with meaningful Interest Coverage only.
OPXA' s Interest Coverage Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: No Debt
F-Score: 3
Z-Score: -12.58
M-Score: -3.00
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -610.15
OPXA's Operating margin (%) is ranked lower than
73% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -70.44 vs. OPXA: -610.15 )
Ranked among companies with meaningful Operating margin (%) only.
OPXA' s Operating margin (%) Range Over the Past 10 Years
Min: -1184.59  Med: -1062.82 Max: -941.04
Current: -610.15
-1184.59
-941.04
Net-margin (%) -608.19
OPXA's Net-margin (%) is ranked lower than
74% of the 700 Companies
in the Global Biotechnology industry.

( Industry Median: -65.41 vs. OPXA: -608.19 )
Ranked among companies with meaningful Net-margin (%) only.
OPXA' s Net-margin (%) Range Over the Past 10 Years
Min: -1314.6  Med: -1248.97 Max: -1183.33
Current: -608.19
-1314.6
-1183.33
ROE (%) -140.13
OPXA's ROE (%) is ranked lower than
87% of the 810 Companies
in the Global Biotechnology industry.

( Industry Median: -30.71 vs. OPXA: -140.13 )
Ranked among companies with meaningful ROE (%) only.
OPXA' s ROE (%) Range Over the Past 10 Years
Min: -654.63  Med: -107.19 Max: -32.36
Current: -140.13
-654.63
-32.36
ROA (%) -86.26
OPXA's ROA (%) is ranked lower than
84% of the 908 Companies
in the Global Biotechnology industry.

( Industry Median: -27.13 vs. OPXA: -86.26 )
Ranked among companies with meaningful ROA (%) only.
OPXA' s ROA (%) Range Over the Past 10 Years
Min: -345.19  Med: -85.56 Max: -24.27
Current: -86.26
-345.19
-24.27
ROC (Joel Greenblatt) (%) -1285.39
OPXA's ROC (Joel Greenblatt) (%) is ranked lower than
64% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: -343.83 vs. OPXA: -1285.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
OPXA' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2807.79  Med: -994.37 Max: -410.49
Current: -1285.39
-2807.79
-410.49
EBITDA Growth (3Y)(%) -19.80
OPXA's EBITDA Growth (3Y)(%) is ranked lower than
70% of the 460 Companies
in the Global Biotechnology industry.

( Industry Median: -2.30 vs. OPXA: -19.80 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
OPXA' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -37.40 Max: 44.5
Current: -19.8
0
44.5
EPS Growth (3Y)(%) -20.10
OPXA's EPS Growth (3Y)(%) is ranked lower than
70% of the 467 Companies
in the Global Biotechnology industry.

( Industry Median: -4.90 vs. OPXA: -20.10 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
OPXA' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: -38.20 Max: 50.1
Current: -20.1
0
50.1
» OPXA's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

OPXA Guru Trades in

OPXA Guru Trades in

Q2 2015

OPXA Guru Trades in Q2 2015

Jim Simons 371,021 sh (New)
» More
Q3 2015

OPXA Guru Trades in Q3 2015

Jim Simons 77,389 sh (-79.14%)
» More
» Details

Insider Trades

Latest Guru Trades with OPXA

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 13.05
OPXA's Forward P/E is ranked higher than
63% of the 344 Companies
in the Global Biotechnology industry.

( Industry Median: 16.75 vs. OPXA: 13.05 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 1.12
OPXA's P/B is ranked higher than
84% of the 1123 Companies
in the Global Biotechnology industry.

( Industry Median: 2.60 vs. OPXA: 1.12 )
Ranked among companies with meaningful P/B only.
OPXA' s P/B Range Over the Past 10 Years
Min: 1.12  Med: 2.75 Max: 11.12
Current: 1.12
1.12
11.12
P/S 4.79
OPXA's P/S is ranked higher than
69% of the 1126 Companies
in the Global Biotechnology industry.

( Industry Median: 8.95 vs. OPXA: 4.79 )
Ranked among companies with meaningful P/S only.
OPXA' s P/S Range Over the Past 10 Years
Min: 4.79  Med: 16.32 Max: 75.27
Current: 4.79
4.79
75.27
EV-to-EBIT 0.19
OPXA's EV-to-EBIT is ranked higher than
99% of the 445 Companies
in the Global Biotechnology industry.

( Industry Median: 20.78 vs. OPXA: 0.19 )
Ranked among companies with meaningful EV-to-EBIT only.
OPXA' s EV-to-EBIT Range Over the Past 10 Years
Min: -1.8  Med: -0.80 Max: 0.2
Current: 0.19
-1.8
0.2
EV-to-EBITDA 0.19
OPXA's EV-to-EBITDA is ranked higher than
99% of the 468 Companies
in the Global Biotechnology industry.

( Industry Median: 17.31 vs. OPXA: 0.19 )
Ranked among companies with meaningful EV-to-EBITDA only.
OPXA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -1.9  Med: -0.80 Max: 0.2
Current: 0.19
-1.9
0.2
Current Ratio 3.25
OPXA's Current Ratio is ranked lower than
60% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.62 vs. OPXA: 3.25 )
Ranked among companies with meaningful Current Ratio only.
OPXA' s Current Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.04 Max: 13.24
Current: 3.25
0.01
13.24
Quick Ratio 3.25
OPXA's Quick Ratio is ranked lower than
57% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. OPXA: 3.25 )
Ranked among companies with meaningful Quick Ratio only.
OPXA' s Quick Ratio Range Over the Past 10 Years
Min: 0.01  Med: 2.04 Max: 13.24
Current: 3.25
0.01
13.24
Days Sales Outstanding 39.80
OPXA's Days Sales Outstanding is ranked higher than
72% of the 560 Companies
in the Global Biotechnology industry.

( Industry Median: 64.60 vs. OPXA: 39.80 )
Ranked among companies with meaningful Days Sales Outstanding only.
OPXA' s Days Sales Outstanding Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 0
Current: 39.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 1.31
OPXA's Price/Net Cash is ranked higher than
89% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 18.00 vs. OPXA: 1.31 )
Ranked among companies with meaningful Price/Net Cash only.
OPXA' s Price/Net Cash Range Over the Past 10 Years
Min: 1.31  Med: 6.51 Max: 217.12
Current: 1.31
1.31
217.12
Price/Net Current Asset Value 1.23
OPXA's Price/Net Current Asset Value is ranked higher than
90% of the 898 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. OPXA: 1.23 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
OPXA' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.19  Med: 5.24 Max: 122.88
Current: 1.23
1.19
122.88
Price/Tangible Book 1.13
OPXA's Price/Tangible Book is ranked higher than
89% of the 1051 Companies
in the Global Biotechnology industry.

( Industry Median: 3.98 vs. OPXA: 1.13 )
Ranked among companies with meaningful Price/Tangible Book only.
OPXA' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.75  Med: 3.80 Max: 119.82
Current: 1.13
0.75
119.82
Price/Median PS Value 0.29
OPXA's Price/Median PS Value is ranked higher than
88% of the 865 Companies
in the Global Biotechnology industry.

( Industry Median: 0.90 vs. OPXA: 0.29 )
Ranked among companies with meaningful Price/Median PS Value only.
OPXA' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.48  Med: 1.10 Max: 4.61
Current: 0.29
0.48
4.61
Earnings Yield (Greenblatt) (%) 505.42
OPXA's Earnings Yield (Greenblatt) (%) is ranked higher than
99% of the 863 Companies
in the Global Biotechnology industry.

( Industry Median: -7.50 vs. OPXA: 505.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
OPXA' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 480.2  Med: 575.30 Max: 13676.1
Current: 505.42
480.2
13676.1

More Statistics

Revenue(Mil) $2
EPS $ -2.57
Beta1.60
Short Percentage of Float4.16%
52-Week Range $1.69 - 7.64
Shares Outstanding(Mil)6.86

Analyst Estimate

Dec15 Dec16 Dec17 Dec18
Revenue(Mil) 3 8 25 100
EPS($) -1.46 -1.14 0.15 0.12
EPS without NRI($) -1.46 -1.14 0.15 0.12

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:P6NP.Germany,
Opexa Therapeutics, Inc., formerly known as PharmaFrontiers Corp., was incorporated in Texas in March 1991. The Company's therapy is based on its proprietary T-cell technology. Opexa initiated a Phase IIb clinical trial of Tcelna in patients with secondary progressive multiple sclerosis. Tcelna has received Fast Track designation from the FDA in secondary progressive multiple sclerosis. Tcelna's combats the demyelination of the nerve fibers in the central nervous system, the underlying cause of multiple sclerosis. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies in the United States and abroad.
» More Articles for OPXA

Headlines

Articles On GuruFocus.com
Weekly CFO Buys Highlight Aug 19 2013 
Opexa Therapeutics Inc. Reports Operating Results (10-K) Mar 08 2011 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Nov 09 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Aug 06 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) May 13 2010 
Opexa Therapeutics Inc. Reports Operating Results (10-Q) Nov 04 2009 

More From Other Websites
Opexa Therapeutics to Present at the 18th Annual BIO CEO and Investor Conference Jan 29 2016
Opexa Therapeutics to Present at the 18th Annual BIO CEO and Investor Conference Jan 28 2016
OPEXA THERAPEUTICS, INC. Financials Dec 08 2015
Opexa Therapeutics, Inc. Earnings Analysis: Q3, 2015 By the Numbers Dec 08 2015
Logic Has Nothing to Do With This Market Nov 24 2015
Computer Games Play the Market Nov 24 2015
4 Stocks to Watch That are Trading Up Today on Heavy Volume Nov 24 2015
And Here Are the Dip Buyers Nov 24 2015
Opexa Therapeutics Chosen as One of the Top Autoimmune Therapy Projects to Watch Nov 17 2015
Opexa Therapeutics Chosen as One of the Top Autoimmune Therapy Projects to Watch Nov 17 2015
Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica (NMO)... Nov 10 2015
Opexa Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update Nov 10 2015
OPEXA THERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Nov 10 2015
OPEXA THERAPEUTICS, INC. Files SEC form 10-Q, Quarterly Report Nov 10 2015
Opexa Therapeutics Announces Supportive Preclinical Study Results for its Neuromyelitis Optica (NMO)... Nov 10 2015
Opexa Therapeutics Reports Third Quarter 2015 Financial Results and Provides Corporate Update Nov 10 2015
Q3 2015 Opexa Therapeutics Inc Earnings Release - After Market Close Nov 10 2015
Opexa Therapeutics Announces News Release Schedule for Third Quarter 2015 Financial Results Nov 06 2015
Opexa Therapeutics Announces News Release Schedule for Third Quarter 2015 Financial Results Nov 06 2015
Chardan Starts Opexa Therapeutics With Buy Rating, $6 Price Target Nov 04 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK